Ascendis Pharma A/S (ASND) Hits New 12-Month High at $46.23

Shares of Ascendis Pharma A/S (NASDAQ:ASND) hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $46.23 and last traded at $40.54, with a volume of 197800 shares changing hands. The stock had previously closed at $39.92.

Several analysts have recently issued reports on ASND shares. Wedbush reiterated an “outperform” rating and issued a $10.71 target price (down previously from $65.00) on shares of Ascendis Pharma A/S in a research report on Friday, September 22nd. Credit Suisse Group reiterated an “outperform” rating and issued a $50.00 target price (up previously from $30.00) on shares of Ascendis Pharma A/S in a research report on Friday, September 22nd. Wells Fargo & Co reiterated a “buy” rating and issued a $51.00 target price on shares of Ascendis Pharma A/S in a research report on Friday, September 22nd. Bank of America reiterated a “buy” rating and issued a $36.00 target price (up previously from $34.00) on shares of Ascendis Pharma A/S in a research report on Monday, September 25th. Finally, HC Wainwright restated a “buy” rating on shares of Ascendis Pharma A/S in a research report on Wednesday, December 13th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $38.79.

The stock has a market capitalization of $1,660.00 and a PE ratio of -11.67.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. RA Capital Management LLC boosted its position in Ascendis Pharma A/S by 3.2% during the second quarter. RA Capital Management LLC now owns 5,580,690 shares of the biotechnology company’s stock worth $154,920,000 after acquiring an additional 170,700 shares during the last quarter. EcoR1 Capital LLC boosted its position in Ascendis Pharma A/S by 44.5% during the second quarter. EcoR1 Capital LLC now owns 1,482,600 shares of the biotechnology company’s stock worth $41,157,000 after acquiring an additional 456,900 shares during the last quarter. VHCP Management II LLC boosted its position in Ascendis Pharma A/S by 31.7% during the third quarter. VHCP Management II LLC now owns 1,299,052 shares of the biotechnology company’s stock worth $47,091,000 after acquiring an additional 312,560 shares during the last quarter. Janus Henderson Group PLC acquired a new position in Ascendis Pharma A/S during the second quarter worth about $15,403,000. Finally, First Manhattan Co. acquired a new position in Ascendis Pharma A/S during the third quarter worth about $12,881,000. Hedge funds and other institutional investors own 78.93% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Ascendis Pharma A/S (ASND) Hits New 12-Month High at $46.23” was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.com-unik.info/2018/01/11/ascendis-pharma-as-asnd-hits-new-12-month-high-at-46-23.html.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit